MedTrace Logo

Screening of Bone Mineral Density in Women Who Have Received Chemotherapy

NCT00603551 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2018-06-19

No results posted yet for this study

Summary

The hypothesis is that postmenopausal women who have received chemotherapy have a greater bone loss than the same age controls. The aim of this study is to obtain baseline bone mineral density (BMD) data on women with breast and gynecological cancers who have received chemotherapy. By comparing the Z scores of postmenopausal women who have received chemotherapy with age matched controls this hypothesis can be evaluated. Another goal of the study is to compare the T-score of a Heel Bone Density Scan to the T-score of the DXA Scan to see if there is a good correlation between peripheral and DXA scores.

Conditions

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • William Creasman, MD · Medical University of South Carolina

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603551 on ClinicalTrials.gov